# BD200

Source: https://onco.cc/drugs/bd200/  
OnCo record `bd200` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BD200 is an experimental multibody-drug conjugate from Biolojic Design, in phase 1 trials for select unresectable locally advanced or metastatic solid cancers.

## Summary

BD200 is a multibody-drug conjugate (dual-binding IgG antibody-drug conjugate) from Biolojic Design. A 'two-in-one' antibody in which each arm can bind either TROP-2 (TROP2) or Nectin-4, used as the base of an antibody-drug conjugate. Its furthest stage is phase 1, for select unresectable locally advanced or metastatic solid cancers. ClinicalTrials.gov registers it in one study linked below. Phase 1a/b NCT07797907 not yet recruiting; estimated start 31 December 2026. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: BD200
- Modality: Multibody-drug conjugate (dual-binding IgG antibody-drug conjugate)
- Mechanism: A 'two-in-one' antibody in which each arm can bind either TROP-2 (TROP2) or Nectin-4, used as the base of an antibody-drug conjugate.

## Sources

- Biolojic Design: biolojic.com: https://biolojic.com/pipeline/
- Biolojic Design: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07797907
- ClinicalTrials.gov: trials of BD200: https://clinicaltrials.gov/search?intr=BD200

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [Nectin-4](https://onco.cc/targets/nectin4/), [TROP2](https://onco.cc/targets/trop2/)
- companies: [Biolojic Design](https://onco.cc/companies/biolojic-design/)
- trials: [This Clinical Study is to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Antitumor Activity of BD200 in Participants With Advanced or Metastatic Cancer.](https://onco.cc/trials/nct07797907/)

---
JSON: https://onco.cc/api/v1/entities/bd200.json